Series sank -1.8% this morning, compared to the S&P 500's day change of 0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:
-
Series has logged a 23.0% 52 week change, compared to 17.3% for the S&P 500
-
COR has an average analyst rating of buy and is -14.05% away from its mean target price of $332.07 per share
-
Its trailing earnings per share (EPS) is $9.74, which brings its trailing Price to Earnings (P/E) ratio to 29.3. The Health Care sector's average P/E ratio is 22.94
-
The company's forward earnings per share (EPS) is $16.36 and its forward P/E ratio is 17.4
-
The company has a Price to Book (P/B) ratio of 27.94 in contrast to the Health Care sector's average P/B ratio is 3.19
-
The current ratio is currently 0.9, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
COR has reported YOY quarterly earnings growth of 45.5% and gross profit margins of 0.0%
-
The company's free cash flow for the last fiscal year was $3.0 Billion and the average free cash flow growth rate is 9.1%
-
Series's revenues have an average growth rate of 9.7% with operating expenses growing at 15.8%. The company's current operating margins stand at 0.7%